Research progress of small peptidomimetics.
- Author:
Jia WANG
;
De-qun SUN
- Publication Type:Journal Article
- MeSH:
Biomedical Research;
trends;
Peptidomimetics;
United States;
United States Food and Drug Administration
- From:
Acta Pharmaceutica Sinica
2015;50(8):931-944
- CountryChina
- Language:Chinese
-
Abstract:
The study of peptide drugs has been an important direction in research and development of new drugs. However, lots of natural macromolecular peptides are limited in clinical use by their metabolic instability and low bioavailability. In recent years, the active small peptidomimetics open up a new hotspot of peptide drug development with the characteristics of low molecular weight, high bioactivity and structural modification. Many peptidomimetics are on the market or on the clinical study. This paper elaborated the small peptidomimetics approved by American Food and Drug Administration (FDA) from 2005 to 2014, and reviewed their researching status with source, synthetic method, chemical structure, marketing time, indication, clinical efficacy and safety. Research prospects in this field were discussed.
